BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35743835)

  • 1. Current Status of Biparametric MRI in Prostate Cancer Diagnosis: Literature Analysis.
    Belue MJ; Yilmaz EC; Daryanani A; Turkbey B
    Life (Basel); 2022 May; 12(6):. PubMed ID: 35743835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
    Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
    BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.
    Arita Y; Akita H; Fujiwara H; Hashimoto M; Shigeta K; Kwee TC; Yoshida S; Kosaka T; Okuda S; Oya M; Jinzaki M
    Eur J Radiol Open; 2022; 9():100403. PubMed ID: 35242886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
    Choi MH; Kim CK; Lee YJ; Jung SE
    AJR Am J Roentgenol; 2019 Apr; 212(4):839-846. PubMed ID: 30779662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
    Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI.
    Chen T; Zhang Z; Tan S; Zhang Y; Wei C; Wang S; Zhao W; Qian X; Zhou Z; Shen J; Dai Y; Hu J
    Front Oncol; 2021; 11():792456. PubMed ID: 35127499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice.
    Zawaideh JP; Sala E; Shaida N; Koo B; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
    Eur Radiol; 2020 Jul; 30(7):4039-4049. PubMed ID: 32166495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
    Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
    Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
    Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of DCE Utility for PCa Diagnosis Using PI-RADS v2.1: Effects on Diagnostic Accuracy and Reproducibility.
    Brancato V; Di Costanzo G; Basso L; Tramontano L; Puglia M; Ragozzino A; Cavaliere AC
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32192081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI).
    Gatti M; Faletti R; Calleris G; Giglio J; Berzovini C; Gentile F; Marra G; Misischi F; Molinaro L; Bergamasco L; Gontero P; Papotti M; Fonio P
    Abdom Radiol (NY); 2019 May; 44(5):1883-1893. PubMed ID: 30788558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
    Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is contrast enhancement needed for diagnostic prostate MRI?
    Scialpi M; Rondoni V; Aisa MC; Martorana E; D'Andrea A; Malaspina CM; Orlandi A; Galassi G; Orlandi E; Scialpi P; Dragone M; Palladino D; Simeone A; Amenta M; Bianchi G
    Transl Androl Urol; 2017 Jun; 6(3):499-509. PubMed ID: 28725592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic performance in clinically significant prostate cancer with PI-RADS version 2.1: simplified bpMRI versus standard mpMRI.
    Song J; Zhao C; Zhang F; Yuan Y; Wang LM; Sah V; Zhang J; Weng W; Yang Z; Wang Z; Wang L
    Abdom Radiol (NY); 2023 Feb; 48(2):704-712. PubMed ID: 36464756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of dynamic contrast-enhanced (DCE) imaging for prostate cancer detection depending on readers experience in prostate MRI.
    Ziayee F; Schimmöller L; Boschheidgen M; Kasprowski L; Al-Monajjed R; Quentin M; Radtke JP; Albers P; Antoch G; Ullrich T
    Clin Radiol; 2024 Mar; 79(3):e468-e474. PubMed ID: 38185579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.
    Prabhu V; Rosenkrantz AB; Otazo R; Sodickson DK; Kang SK
    J Magn Reson Imaging; 2019 May; 49(5):1400-1408. PubMed ID: 30629317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.